Goldman Sachs analyst Richard Law initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $30 price target The company’s lead asset, VK2735, is a dual GLP-1/GIP agonist being developed in subcutaneous and oral formulations for obesity, the analyst tells investors in a research note. The firm says that while the Phase 2 results suggest a “highly potent” and safe drug that can rival standards of care and next-generation therapies, its analyses of the commercial landscape reveal a “hyper competitive obesity market with high barriers to entry.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Cautious Hold Rating for Viking Therapeutics Amid Competitive Obesity Market Challenges
- GameStop, Dell, Zscaler, Schlumberger, Viking: Insider Moves!
- Viking Therapeutics’ Promising VK2735 Trials and Strategic Advancements Drive Buy Rating
- Viking Therapeutics’ Strategic Advancements and Promising VK2735 Trial Support Buy Rating
- Positive Outlook for Viking Therapeutics: Strong Trial Enrollment and Upcoming Milestones Suggest Upside Potential
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue